Emerging from the Darkness. Sudden Cardiac Death in Cardiac Amyloidosis

Area of Science:

• Cardiology
• Cardiovascular Pathology
• Electrophysiology

Background:

• Cardiac amyloidosis (CA) presents as infiltrative cardiomyopathy with a hypertrophic pattern, often leading to heart failure with preserved ejection fraction.
• Degenerative valvular heart disease, especially severe aortic stenosis, is frequently observed in CA patients.
• Amyloid deposition in the conduction system can cause electrical disorders like ventricular tachyarrhythmias and atrio-ventricular block.

Purpose of the Study:

• To review the pathophysiological mechanisms of sudden cardiac death (SCD) in cardiac amyloidosis.
• To identify key risk factors contributing to SCD in CA.
• To discuss current challenges and concerns in the medical and device management of SCD risk in CA.

Main Methods:

• Literature review focusing on pathophysiological mechanisms, risk factors, and management strategies for sudden cardiac death in cardiac amyloidosis.
• Synthesis of current evidence on the clinical manifestations and electrophysiological consequences of amyloid fibril deposition in the heart.
• Analysis of contemporary approaches to medical and device-based interventions for managing SCD risk in CA.

Main Results:

• Amyloid infiltration of the myocardium and conduction system significantly elevates the risk of sudden cardiac death in CA.
• Common manifestations include heart failure with preserved ejection fraction, severe aortic stenosis, and conduction abnormalities.
• Electrical disorders such as ventricular tachyarrhythmias, atrio-ventricular block, and electromechanical dissociation are critical contributors to SCD.

Conclusions:

• Cardiac amyloidosis poses a substantial risk for sudden cardiac death due to its profound effects on cardiac structure and electrical function.
• Understanding the specific pathophysiological pathways and risk factors is crucial for effective management.
• Addressing the complexities of medical and device management is essential to mitigate SCD risk in this patient population.